nach oben

Erschienen in:

27.10.2024 | Research

Incidence of infection in patients with acute myeloid leukemia receiving high-dose cytarabine consolidation

verfasst von: Kristen McClellan, Julia Messina, Jennifer Saullo, Jonathan Huggins

Erschienen in: Annals of Hematology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Infection risk during high-dose cytarabine (HiDAC) consolidation following induction therapy for acute myeloid leukemia (AML) is not well understood complicating decisions regarding antimicrobial prophylaxis during this period. We performed a retrospective chart review of adult patients with AML undergoing HiDAC consolidation between June 2016 and November 2021 at our institution. The primary endpoint was microbiologically confirmed infection within 30 days of HiDAC administration. This study included 111 patients who received a total of 264 cycles of HiDAC therapy. 36% of patients undergoing HiDAC consolidation had at least 1 infection over the course of their consolidation therapy. Infection complicated 18% of HiDAC cycles. The majority of infections were bacterial (81%), primarily caused by gram-negative organisms. Fluoroquinolone prophylaxis was associated with a lower hazard of bacterial infection (HR 0.46, 95% CI 0.24, 0.88). However, 26% of bacterial infections broke through antibiotic therapy with multiple cases concerning for fluoroquinolone resistance. Viral and fungal infections were rare (14% and 3% of infections respectively).

Nur mit Berechtigung zugänglich

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):e56–93. https://doi.org/10.1093/cid/cir073CrossRefPubMed

Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, Cooper B, Dubberke ER, Engemann AM, Freifeld AG, Greene JN, Ito JI, Kaul DR, Lustberg ME, Montoya JG, Rolston K, Satyanarayana G, Segal B, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW, Hoffmann KG, Smith C (2016) Prevention and Treatment of Cancer-related infections, Version 2.2016, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 14(7):882–913. https://doi.org/10.6004/jnccn.2016.0093CrossRefPubMed

Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I (2010) Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 116(4):967–973. https://doi.org/10.1002/cncr.24812CrossRefPubMed

Sousa J, Alves G, Fortuna A, Falcão A (2014) Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Curr Drug Saf 9(2):89–105. https://doi.org/10.2174/1574886308666140106154754CrossRefPubMed

Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331(14):896–903. https://doi.org/10.1056/nejm199410063311402

De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6(7):e441. https://doi.org/10.1038/bcj.2016.50CrossRefPubMedPubMedCentral

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196CrossRefPubMedPubMedCentral

Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O’Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, Hammond L, Ogba N (2019) Acute myeloid leukemia, Version 3.2019, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 17(6):721–749. https://doi.org/10.6004/jnccn.2019.0028CrossRefPubMed

Buckley SA, Othus M, Vainstein V, Abkowitz JL, Estey EH, Walter RB (2014) Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. Am J Hematol 89(4):423–428. https://doi.org/10.1002/ajh.23661CrossRefPubMedPubMedCentral

10.

Kawasaki Y, Kimura SI, Nakano H, Mashima K, Shirato Y, Kawaguchi SI, Toda Y, Ochi SI, Nagayama T, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Fujiwara SI, Ohmine K, Kako S, Muroi K, Kanda Y (2019) Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index. Int J Hematol 109(4):470–476. https://doi.org/10.1007/s12185-019-02593-2CrossRefPubMed

11.

Owattanapanich W, Chayakulkeeree M (2019) Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis. Hematology 24(1):362–368. https://doi.org/10.1080/16078454.2019.1589706CrossRefPubMed

12.

Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353(10):977–987. https://doi.org/10.1056/NEJMoa044097CrossRefPubMed

13.

Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, Kremer LC, Leibovici L (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 1(1):Cd004386. https://doi.org/10.1002/14651858.CD004386.pub3CrossRefPubMed

14.

Chung SJ, Miller RA, Permpalung N, Baker AW, Diehl LF, Rizzieri DA, Alexander BD (2019) Fluoroquinolone prophylaxis reduces febrile neutropenia, bloodstream infections from mucosal translocations, and intensive care admissions in high risk hematological patients, a single center experience. Leuk Lymphoma 60(2):488–492. https://doi.org/10.1080/10428194.2018.1488252CrossRefPubMed

15.

Wolf J, Tang L, Flynn PM, Pui C-H, Gaur AH, Sun Y, Inaba H, Stewart T, Hayden RT, Hakim H, Jeha S (2017) Levofloxacin Prophylaxis during induction therapy for Pediatric Acute Lymphoblastic Leukemia. Clin Infect Dis 65(11):1790–1798. https://doi.org/10.1093/cid/cix644CrossRefPubMedPubMedCentral

16.

Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M (2007) Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 25(34):5471–5489. https://doi.org/10.1200/jco.2007.12.3851CrossRefPubMed

17.

Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N (1999) Randomized placebo-controlled trial of Fluconazole Prophylaxis for Neutropenic Cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 28(2):331–340. https://doi.org/10.1086/515128CrossRefPubMed

18.

CDC/NHSN Surveillance Definitions for Specific Types of Infections (2020)

19.

Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrisey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG (2020) Revision and update of the Consensus definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 71(6):1367–1376. https://doi.org/10.1093/cid/ciz1008CrossRefPubMed

20.

Kalaskar P, Anand A, Panchal H, Patel A, Parikh S, Shah S (2017) A comparative study of bloodstream infections in acute myeloid leukemia according to different phases of treatment: can we predict the organism? South Asian J Cancer 6(3):132–133. https://doi.org/10.4103/2278-330x.214584CrossRefPubMedPubMedCentral

21.

Saini L, Rostein C, Atenafu EG, Brandwein JM (2013) Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant E. Coli. BMC Infect Dis 13:284. https://doi.org/10.1186/1471-2334-13-284CrossRefPubMedPubMedCentral

22.

Vale CA, Egan PC, Ingham R, Farmakiotis D, Reagan JL (2021) Antibiotic use during cytarabine consolidation in acute myeloid leukemia. Ann Hematol 100(1):79–84. https://doi.org/10.1007/s00277-020-04238-5CrossRefPubMed

23.

Kusick K, Earl M, Gallagher EM, Yeh J-Y, Advani AS, Kalaycio M, Copelan EA, Sekeres MA (2011) Fluoroquinolone Prophylaxis in Acute myeloid leukemia (AML) patients undergoing Post-remission Chemotherapy reduces Hospital Admission Rates. Blood 118(21):2570. https://doi.org/10.1182/blood.V118.21.2570.2570CrossRef

24.

Lee SSF, Fulford AE, Quinn MA, Seabrook J, Rajakumar I (2018) Levofloxacin for febrile neutropenia prophylaxis in acute myeloid leukemia patients associated with reduction in hospital admissions. Support Care Cancer 26(5):1499–1504. https://doi.org/10.1007/s00520-017-3976-1CrossRefPubMed

25.

De Rosa FG, Motta I, Audisio E, Frairia C, Busca A, Di Perri G, Marmont F (2013) Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis 13:563. https://doi.org/10.1186/1471-2334-13-563CrossRefPubMedPubMedCentral

Titel: Incidence of infection in patients with acute myeloid leukemia receiving high-dose cytarabine consolidation
verfasst von: Kristen McClellan
Julia Messina
Jennifer Saullo
Jonathan Huggins
Publikationsdatum: 27.10.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 12/2024
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-06069-0

Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis

Review

Neutrophil extracellular traps - an a-list-actor in a variety of diseases

Review

Survival impact of hypoxia-inducible factor-1 alpha (HIF-1α) in Nucleophosmin1 mutated acute myeloid leukemia

Research

Novel biallelic GNE variants identified in a patient with chronic thrombocytopenia without any symptoms of myopathy

Case Report

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Research

Metabolic tumor volume from baseline [18 F]FDG PET/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma

Research

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

22.01.2025
Prostatakarzinom
Nachrichten

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Leitlinienkonformes Management thermischer Verletzungen

22.01.2025
Verbrennung
Nachrichten

Thermische Verletzungen gehören zu den schwerwiegendsten Traumen und hinterlassen oft langfristige körperliche und psychische Spuren. Die aktuelle S2k-Leitlinie „Behandlung thermischer Verletzungen im Kindesalter (Verbrennung, Verbrühung)“ bietet eine strukturierte Übersicht über das empfohlene Vorgehen.

Frühe Hyperoxie nach Reanimation mit Folgen für die Prognose?

22.01.2025
Kardiopulmonale Reanimation
Nachrichten

Kommt es sehr früh nach einer kardiopulmonalen Reanimation zu einem Zustand der Hyperoxie, ist dies bei Patienten nach einem Herzstillstand mit schlechteren funktionellen Ergebnissen assoziiert. Das zeigt eine Sekundäranalyse der TTM-2-Studie.

Antibiotika bei Bakteriämie: 7 versus 14 Tage

21.01.2025
Sepsis
Nachrichten

Eine Bakteriämie lässt sich mit einer einwöchigen Antibiotikatherapie zumeist gut in den Griff bekommen: Die Sterberate ist nicht höher als unter zweiwöchiger Behandlung, zeigt eine Vergleichsstudie mit hospitalisierten Erkrankten. Allerdings muss die Therapie bei fast jedem Vierten verlängert werden.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Incidence of infection in patients with acute myeloid leukemia receiving high-dose cytarabine consolidation

Abstract

Weitere Artikel der Ausgabe 12/2024

Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis

Neutrophil extracellular traps - an a-list-actor in a variety of diseases

Survival impact of hypoxia-inducible factor-1 alpha (HIF-1α) in Nucleophosmin1 mutated acute myeloid leukemia

Novel biallelic GNE variants identified in a patient with chronic thrombocytopenia without any symptoms of myopathy

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Metabolic tumor volume from baseline [18 F]FDG PET/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

Leitlinienkonformes Management thermischer Verletzungen

Frühe Hyperoxie nach Reanimation mit Folgen für die Prognose?

Antibiotika bei Bakteriämie: 7 versus 14 Tage

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten